Clinical Chemistry Analyzer Patents: Who Leads, Where the Gaps Are 2026
- 34.0% concentration. The top 5 of 100 ranked assignees hold 127 of the 373 records in scope — a third of the field sits with a handful of filers.
- Filing has plateaued, not fallen. 2021 to 2024 (the last complete year) held flat at 4 filings each, a 0% change — read later years as still filling in, not as decline.
- G01N dominates, G01J is the second axis. 76.7% of records touch material analysis (G01N) and 22.8% touch radiation/light measurement (G01J), pointing to optical path and detection as the live design battleground.
Filing growth compares 2021 (4 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 373 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Clinical chemistry analyzer design sits at the intersection of fluidics, optics and consumable handling: cuvette washing cycles, reagent onboard stability, carryover control, optical path geometry, throughput per hour and maintenance intervals are the recurring claim elements across the 373 records in this dataset. The search deliberately pulls in adjacent instrumentation language — photometric analyzer, biochemistry analyzer — because claim drafting in this space borrows heavily across those terms.
Coverage runs from 2015-01-01 to the 2026-07-31 cut-off. Because publication lags filing by roughly 18 months, the most recent one to two years in any trend chart understate real filing activity and should not be read as a slowdown on their own.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 373 records: how filing volume has moved year over year, and which IPC subclasses carry the claim language.
Filing trend, 2017–2026
Filings peaked at 16 in 2017 and have since settled into a lower, flatter band; the 2021→2024 span held at 4 filings each year, a 0% change over that complete window. Years after 2024 are still incomplete due to publication lag and should not be compared directly against 2024.
IPC technology composition
G01N (material analysis & testing) appears in 76.7% of the 373 records, confirming this as a material-analysis-first field rather than a pure optics or fluidics one. G01J (radiation & light measurement) at 22.8% and B01L (lab apparatus) at 13.4% form the next tier, with A61B, E21B, A61M, G01V and C12Q each present in a smaller but non-trivial slice — note that because records can carry multiple classes, these shares sum to well over 100% of the record total.
Shares are the percentage of the 373 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Clinical Chemistry Analyzer Design with Eureka
This page is one run against one query. Ask Eureka your own question about clinical chemistry analyzer design and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited records
US4078896A — Photometric analyzer (ITT Corporation, 1978-03-14)
A photometric analyzer to monitor one or more constituents of a mixture, such as by producing indications of the concentrations of sulfur dioxide and NOX (NO + NO2) in flue gases. The NO is converted to detectable NO2 by ozone.Included as a foundational optical-detection reference; its filing predates the modern clinical chemistry analyzer claim set by decades and its scope is narrower than the current field.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6319469B1 | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system | 638 |
| 2 | US5314825A | Chemical analyzer | 523 |
| 3 | US20070060872A1 | Apparatus and methods for analyzing body fluid samples | 348 |
| 4 | US6632399B1 | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system for … | 272 |
| 5 | US20060189926A1 | Apparatus and methods for analyzing body fluid samples | 262 |
| 6 | US20010055812A1 | Devices and method for using centripetal acceleration to drive fluid movement in a microfluidics system with … | 255 |
| 7 | US20090117620A1 | Automated analyzer for clinical laboratory | 240 |
| 8 | US20070179436A1 | Analyte detection system with periodic sample draw and laboratory-grade analyzer | 236 |
| 9 | US6709869B2 | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system | 230 |
| 10 | US20020137218A1 | Devices and methods for using centripetal acceleration to drive fluid movement in a microfluidics system | 218 |
Citation counts inside this corpus favour older filings that have had more time to accumulate citations; treat them as a signal of influence on subsequent drafting, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that change how a freedom-to-operate or whitespace search should be scoped in this field.
A third of the field sits with five assignees
The top 5 of the 100 ranked assignees account for 127 of the 373 records in scope, and the top 10 push that to 51.2%. That is a genuinely concentrated core sitting above a long tail of single- or few-filing entrants — new entrants should expect the densest prior art near the leaders' core claim language rather than spread evenly across the field.
Flat, not declining
Filing volume held at 4 per year from 2021 to 2024, the last year that can be treated as complete. The leading assignees in the recent-momentum data show 0 filings in the latest year across the board, which is consistent with publication lag rather than an actual pullback from the space.
Material analysis is the anchor class
G01N appears in more than three-quarters of records, with G01J (radiation & light measurement, 22.8%) as the clear second axis. The presence of E21B and G01V — earth/rock drilling and geophysics — at meaningful minority shares reflects cross-filing from downhole fluid analysis instrumentation into the same claim language, a detail worth checking before assuming a hit is purely clinical.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to clinical chemistry analyzer design, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Roche Diagnostics GmbH | F. Hoffmann-La Roche & Co AG | 15 |
| BRAIG JAMES R | KEENAN RICHARD | 9 |
| BRAIG JAMES R | RULE PETER | 8 |
| OPTISCAN BIOMEDICAL CORP | BRAIG JAMES R | 7 |
| OPTISCAN BIOMEDICAL CORP | KEENAN RICHARD | 6 |
| BRAIG JAMES R | WITTE KENNETH G | 5 |
| BRAIG JAMES R | HALL W DALE | 5 |
| BRAIG JAMES R | GABLE JENNIFER H | 5 |
Ten co-assignee pairs are recorded, with the strongest pairing appearing on 15 shared records and two named-inventor pairs appearing on 9 and 8 records respectively — evidence of stable internal teams rather than cross-company joint filing.
Who holds the core claims
The ranked leaders combine large diagnostics instrument makers with a handful of names whose presence looks incidental until the shared IPC classes are checked.
One assignee well ahead of the field
The leading assignee holds 30 records against a fifth-place figure of 19 and a tenth-place figure of 10 — a steep drop-off that marks this as a leader-plus-cluster structure rather than an even spread.
US filing dominates, EPO and PCT follow
United States filings lead at 131, with Europe (EPO) at 70 and WIPO/PCT at 34. Canada, Japan and Australia each sit in the low twenties, indicating this is a field where US prosecution sets the pace and other jurisdictions largely mirror it rather than lead it.
Oilfield instrumentation makers are present
Names associated with drilling and downhole services appear in the ranked assignee list alongside diagnostics companies, tracing back to the E21B and G01V classes. A search that assumes every hit is a hospital-bench analyzer will miss this overlap and misjudge how contested a given claim actually is.
| Assignee | Recent year | YoY |
|---|---|---|
| PRECISION ENERGY SERVICES INC | 0 | — |
| Dade Behring Inc | 0 | — |
| OPTISCAN BIOMEDICAL CORP | 0 | — |
| Abbott Laboratories | 0 | — |
| Roche Diagnostics GmbH | 0 | — |
| F. Hoffmann-La Roche & Co AG | 0 | — |
| Halliburton Energy Services Inc | 0 | — |
| Siemens Healthcare Diagnostics Inc | 0 | -100% |
Where to take this analysis
The dataset points to specific follow-up work depending on whether the goal is freedom-to-operate, whitespace filing, or monitoring.
Run a claim-level FTO check near the leaders
With 34.0% of records held by five assignees, a freedom-to-operate search should start with those assignees' core claims in G01N and G01J before widening.
Explore assignee claims in EurekaScope a whitespace filing in an under-claimed branch
Sub-areas like carryover detection via optical signature and maintenance-interval self-diagnostics show lighter density relative to the core cluster and warrant a targeted novelty search.
Run a whitespace search in EurekaTrack the two most-cited fluidics families
The centripetal-acceleration microfluidics filings carry the highest citation counts in this set and shape how later claims are drafted around fluid movement in analyzer cartridges.
Trace citation trees in EurekaCommon questions on this landscape
Across the 373 records in this dataset, the leading assignee holds 30 records, with the fifth-ranked assignee at 19 and the tenth-ranked at 10. The top 5 assignees together account for 34.0% of all 373 records, and the top 10 account for 51.2%. That leaves a long tail of the remaining ranked companies with far fewer filings each, so due diligence should weight the leaders' claims most heavily but not ignore the tail entirely.
Filing activity peaked at 16 records in 2017 and has since settled lower. Between 2021 and 2024, the last year that can be treated as complete, filings held flat at 4 per year, a 0% change. Figures for 2025 and 2026 appear lower still, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity, so it is premature to call this a declining field.
G01N, material analysis and testing, appears in 76.7% of the 373 records and is by far the dominant class. G01J, radiation and light measurement, follows at 22.8%, and B01L, lab apparatus, at 13.4%. Because a single record can carry multiple IPC classes, these percentages overlap rather than sum to 100%, but the pattern is clear: optical detection and material analysis are the two axes where claim density is highest.
The IPC and citation data point to lighter claim density in areas like automated cuvette wash-cycle optimisation, carryover detection via optical signature, and maintenance-interval self-diagnostics compared with the dense core around optical path and reagent handling claims. These are not guaranteed clear, but they sit outside the heaviest-filed cluster and merit a targeted novelty search before drafting. A first claim there would typically combine a specific sensing or diagnostic step with the analyzer's existing fluidics or optical hardware rather than claiming the hardware itself.
Yes. The dataset shows meaningful overlap with earth and rock drilling (E21B, 7.2% of records) and geophysics (G01V, 5.9%), because downhole fluid analysis instrumentation shares claim language with clinical photometric and material-analysis techniques. A search limited to diagnostics-industry assignees alone will miss these cross-domain filings, which can still be cited against a clinical chemistry analyzer application if the underlying optical or fluidic mechanism overlaps.
Research Clinical Chemistry Analyzer Design in depth with Eureka
Go past this page: query the whole clinical chemistry analyzer design corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.